Journal article icon

Journal article

Long-term cardiac effects of adrenalectomy versus surveillance in mild cortisol excess: 5-year results from the prospective ITACA study

Abstract:
Objective: To determine whether cardiac remodelling associated with mild autonomous cortisol secretion (MACS) is reversible after treatment and how trajectories compare with non-functioning adrenal incidentalomas (NFAI). Design: Five-year prospective cohort study (ITACA; NCT04127552). Methods: Sixty patients (35 MACS, 25 NFAI) underwent clinical, biochemical, and echocardiographic evaluations at baseline and after 1 and 5 years. MACS was managed with either active surveillance (AS, n = 22) or unilateral adrenalectomy (ADRX, n = 13). Longitudinal changes were analysed with linear mixed-effects models. Results: At baseline, MACS had a higher prevalence of left-ventricular (LV) hypertrophy (46% vs 16%, P = .013) and diastolic dysfunction (34% vs 12%, P = .050), and greater LV mass index (LVMi) (median 100 vs 85 g/m², P = .011). Over time, the change in LVMi differed between NFAI, MACS-AS and MACS-ADRX (P = .004). At 1 year, LVMi fell by −14.8 g/m² (95%CI −28.7 to −0.9) after ADRX and rose by 13.7 g/m² (0.8 to 26.5) under AS. By 5 years, LVMi returned to baseline in both MACS subgroups, whereas NFAI increased by 22.4 g/m² (12.3 to 32.5; P < .001). Right-ventricular systolic excursion (TAPSE) improved only in AS (3.6 mm, 1.8 to 5.4; P = .001). Global LV systolic and diastolic indices deteriorated similarly across groups. Major adverse cardiac events occurred in 13.3% of MACS-AS, 12.5% of ADRX, and 5.6% of NFAI patients. Conclusions: MACS is associated with early concentric LV remodelling that regresses after adrenalectomy but rebounds within 5 years, leaving surgical and surveillance patients with comparable cardiac geometry. Under AS, remodelling stabilizes, whereas NFA continue a slow, progressive hypertrophic course. These findings support serial echocardiographic monitoring and underscore the need to test other cortisol-lowering therapies, alone or in combination with surgery, for durable cardioprotection.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1093/ejendo/lvag018

Authors

More by this author
Role:
Author
ORCID:
0000-0001-5242-1761
More by this author
Role:
Author
ORCID:
0009-0004-3803-4350
More by this author
Role:
Author
ORCID:
0000-0002-9385-9097
More by this author
Role:
Author
ORCID:
0000-0002-9333-5189


Publisher:
Oxford University Press
Journal:
European journal of endocrinology More from this journal
Volume:
194
Issue:
2
Pages:
170-184
Article number:
lvag018
Publication date:
2026-01-23
Acceptance date:
2026-01-19
DOI:
EISSN:
1479-683X
ISSN:
0804-4643


Language:
English
Keywords:
Pubs id:
2366161
Local pid:
pubs:2366161
Source identifiers:
3745010
Deposit date:
2026-02-10
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP